Combination therapy achieves 82% tumor response rate in advanced pancreatic cancer trial
Reported bySTAT News ↗·Sourced by Goodlede
A combination of Tango Therapeutics' experimental drug and Revolution Medicines' Rasonque led to tumor responses in 82% of patients with advanced pancreatic cancer, with 88% of responders still alive without tumor progression at nine months.
Results are from a clinical trial; the therapy has not yet received regulatory approval and further studies are needed to confirm long-term effectiveness.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at STAT News
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede